PeptidePedia The community reference

Sarcopenia: difference between revisions

Diff·revision 9 → 10·09:30, 8 Mar 2025

Difference between revision 9 and revision 10 of Sarcopenia. 6 lines changed; the page grew by 581 bytes.

Revision 9 — 04:25, 24 Feb 2025
B12_Bettina (talk)
split the analytical performance from the clinical interpretation
2,738 bytes ±0
Revision 10 — 09:30, 8 Mar 2025
AnalyticalAnnie (talk)
state the assay the reference interval was established on
3,319 bytes +581
1{{Infobox concept1{{Infobox concept
2| name = Sarcopenia2| name = Sarcopenia
+3| subtitle = Clinical practice
3| Defined by = Low muscle strength, confirmed by low muscle quantity4| Defined by = Low muscle strength, confirmed by low muscle quantity
4| Assessed by = Grip strength, chair-stand time, gait speed5| Assessed by = Grip strength, chair-stand time, gait speed
2425
25Sarcopenic obesity — low muscle with high fat mass — is a recognised phenotype and is harder to detect, since body weight does not signal it and the muscle deficit is concealed by adiposity.{{r|heymsfield2015}}26Sarcopenic obesity — low muscle with high fat mass — is a recognised phenotype and is harder to detect, since body weight does not signal it and the muscle deficit is concealed by adiposity.{{r|heymsfield2015}}
+27
+28== Relevance to weight reduction ==
+29All substantial weight loss reduces lean mass to some degree, and the compartment includes organ and water components as well as muscle. See [[Body composition assessment]].{{r|heymsfield2015}}
+30
+31The specific question — whether pharmacological weight loss reduces muscle disproportionately compared with equivalent loss by other means — is not answered by existing trials, which measured composition in subsets as a secondary outcome and compared against placebo arms losing little weight.{{r|wilding2021}}
2632
27== References ==33== References ==